Abstracts Archive - Page 101 of 2425 - ACR Meeting Abstracts

Abstract Number: 0528 • ACR Convergence 2024
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort
Sandra Carrillo¹, Daniel Xibille², Martha Mariana Castañeda-Martínez³, Alfredo Reyes⁴, Brian garcia-Arellano⁵, Edgar Vega Chávez⁶, Carlos vidal Montiel Castañeda⁵, Gabriel Carmona Lara⁶ and Gilberto De Hoyos⁵, ¹Hospital Angeles Lindavista, Mexico City, Distrito Federal, Mexico, ²Servicios de Salud de Morelos, Cuernavaca, Morelos, Mexico, ³ISSSTE, Monterrey, Mexico, ⁴ISSSTE, Ciudad de México, Mexico, ⁵ISSSTE, Ciudad de México, Distrito Federal, Mexico, ⁶ISSSTE, Ciudad de mexico, Distrito Federal, Mexico
Background/Purpose: Biological agents such as the TNF-α inhibitors have had a positive impact on the treatment of many chronic autoimmune diseases (AIDs), such as Rheumatoid…
Abstract Number: 0782 • ACR Convergence 2024
30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis
Sylvia Posso¹, Jane Buckner², Montserrat Anguera³ and Nikhil Jiwrajka⁴, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is a heavily female-biased systemic autoimmune disease associated with significant morbidity and mortality due to fibrosis of the skin and vital…
Abstract Number: 1015 • ACR Convergence 2024
Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Viet Bui¹, Miguel Rodriguez² and Sarah Ormseth³, ¹Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, ²Texas Arthritis Center, El Paso, TX, ³The Lundquist Institute, Torrance, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0956 • ACR Convergence 2024
Secreted Frizzled-Related Protein 2 (sFRP2) Regulates Wnt Signaling to Affect Mesenchymal Transition of Lung Epithelial Cells Participates in Interstitial Lung Disease
Yinlan Wu¹, Yanhong Li² and Yi Liu³, ¹West China Hospital of Sichuan University, Chengdu, Sichuan, China, ²West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ³West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Investigation of Transcriptional Changes in Interstitial Lung Disease (ILD) and Exploration of Functional Effects of Differential Genes and Expressed Proteins in the Development of…
Abstract Number: 0535 • ACR Convergence 2024
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Pauline Bovens¹, Luuk Van Esveld², Maike Wientjes¹, Noortje van Herwaarden³, David Ten Cate⁴, Eward Melis³, Nienke Lesuis⁵, Bart van den Bemt⁶ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Utrecht, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Rotterdam, Netherlands, ⁵Hospital Group Twente, Almelo, Netherlands, ⁶Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
Abstract Number: 0792 • ACR Convergence 2024
Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Yusuf Yazici¹, Jeyanesh Tambiah², Christopher Swearingen³ and Timothy McAlindon⁴, ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴University of Massachusets, Worchester, MA
Background/Purpose: Knee OA has unmet need for safe and efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory…
Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
Abstract Number: 1005 • ACR Convergence 2024
Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral
Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 0966 • ACR Convergence 2024
CDDO-Me Attenuates Pro-fibrotic Activation in Macrophages and Fibroblasts in Systemic Sclerosis
Heetaek Yang¹, Chanhyuk Park², Chen-Yu Wang³, Emily Morris⁴, Karen Liby⁵, Michael Whitfield⁶ and Patricia Pioli², ¹Dartmouth College, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth College, Enfield, NH, ⁵Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is characterized by dysfunctional immune activation, oxidative stress, and fibrosis. In prior work, we have shown that SSc macrophages (MØs) have…
Abstract Number: 0542 • ACR Convergence 2024
Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Clementina López Medina¹, Sofia Ramiro², Dafne Capelusnik³ and Anna Molto⁴, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Leiden University Medical Center, Bunde, Netherlands, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Kaleb Michaud¹, Shreena Kamlesh Gandhi², Sofia Pedro³, Cassandra Calabrese⁴, Patti Katz⁵ and Leonard Calabrese⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Kansas University School of Medicine - Wichita, Wichita, KS, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Cleveland Clinic Foundation, Cleveland Heights, OH, ⁵UCSF, San Rafael, CA, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…
Abstract Number: 0891 • ACR Convergence 2024
Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells
Jacquelyn Nestor¹, Rachelly Normand¹, Wamia Said¹, Sergio Aguilar², Nandini Samanta¹, Sidney Martin¹, Roya Best¹, Hoang Anh Tran¹, Adrien Antoinette¹, Eilish Dillon³, Devin King³, April Jorge⁴, Maureen Leonard⁴, Pritha Sen³, Kerry Reynolds⁴, John Stone⁵, Michelle Rengarajan¹, Tanuja Chitnis⁶, Kevin Wei⁷, Deepak Rao³, Andrew Luster⁸, Gary Reynolds¹ and Alexandra-Chloe Villani¹, ¹Massachusetts General Hospital, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, MA, ²National Center for Genomic Analysis, Barcelona, Spain, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁸Massachusetts General Hospital, Charlestown, MA
Background/Purpose: Rheumatologic diseases are characterized by distinct clinical presentations and patterns of organ involvement, yet share many genetic risk factors and treatment responses. This suggests…
Abstract Number: 0025 • ACR Convergence 2024
Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis
Shivmurat Yadav¹, Timothy Griffin², Matlock Jeffries², Stavros Stavrakis³ and Mary Beth Humphrey⁴, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma, College of Mediicine, Oklahoma City, OK, ⁴University of Oklahoma College of Medicine, Oklahoma City, OK
Background/Purpose: Osteoarthritis (OA) causes joint pain, stiffness, swelling, and functional impairment. Pain signals reach the brain, influencing inflammatory and immune responses through the parasympathetic efferent…
Abstract Number: 0061 • ACR Convergence 2024
Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways
Joshua Sciurba¹, Daniel Kass¹, Eleanor Valenzi², John Sembrat², Robert Lafyatis³ and Dana Ascherman⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Transcriptional profiling represents a powerful tool for deciphering disease-relevant pathways and deriving functional biomarkers. Given the shared demographic, genetic, and clinico-epidemiologic features between rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].